Equities

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)8.39
  • Today's Change-0.37 / -4.22%
  • Shares traded1.49m
  • 1 Year change-83.61%
  • Beta1.1719
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold1
Sell2
Strong Sell2

Share price forecast in USD

The 5 analysts offering 12 month price targets for Ginkgo Bioworks Holdings Inc have a median target of 10.00, with a high estimate of 10.00 and a low estimate of 7.00. The median estimate represents a 19.19% increase from the last price of 8.39.
High19.2%10.00
Med19.2%10.00
Low-16.6%7.00

Earnings history & estimates in USD

On Aug 08, 2024, Ginkgo Bioworks Holdings Inc reported 2nd quarter 2024 losses of -2.80 per share. This result exceeded the -3.12 consensus loss of the 5 analysts covering the company and exceeded last year's 2nd quarter results by 22.22%.
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate-1.69%
Ginkgo Bioworks Holdings Inc reported annual 2023 losses of -18.40 per share on Feb 29, 2024.
Average growth rate+33.52%
More ▼

Revenue history & estimates in USD

Ginkgo Bioworks Holdings Inc had 2nd quarter 2024 revenues of 56.21m. This bettered the 43.14m consensus of the 5 analysts covering the company. This was 30.35% below the prior year's 2nd quarter results.
Average growth rate-2.80%
Ginkgo Bioworks Holdings Inc had revenues for the full year 2023 of 251.46m. This was 47.36% below the prior year's results.
Average growth rate+2.43%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.